Market Access News | pharmaphorum

News

NICE backs Novartis duo for NHS use in young glioma patients

An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use

News

EU OK sets up first ex-China launches for BeiGene's Tevimbra

BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside

News

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product.

News

EU approves Pfizer antibiotic for superbug infections

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections.

News

NICE backs wider NHS use of multiple myeloma drug Nexpovio

More than 1,000 people with incurable blood cancer multiple myeloma could be eligible for treatment with Menarini Stemline UK’s Nexpovio after NICE backed NHS use of the d

News

FDA clears Roche’s Alecensa for adjuvant use in NSCLC

Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,

NICE backs Novartis duo for NHS use in young glioma patients

EU OK sets up first ex-China launches for BeiGene's Tevimbra

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

EU approves Pfizer antibiotic for superbug infections

NICE backs wider NHS use of multiple myeloma drug Nexpovio

FDA clears Roche’s Alecensa for adjuvant use in NSCLC

BridgeBio gains on phase 3 dwarfism data

How to meet your physicians where they are online

News

Editor's Picks